Prior authorization policies are commonly used by Medicaid programs to control psychotropic drug expenditures. This study examined the association of a prior-authorization policy for atypical antipsychotic and anticonvulsant agents with medication discontinuation and use of health services among patients with bipolar disorder.
Prior Authorization policies for psychotropic medications in Medicaid
psychiatric patient populations have led to poor outcomes. 1. Increased medication discontinuation, lapses in care (around 26% of patients) 2. Amongst those with lapses in care, around 80% experience adverse consequences (a rate of 3.6 times more) such as: i. Increased utilization of emergency/crisis services ii. Homelessness iii. Incarceration iv. Lost wages v. Higher medical costs 2. Placing the burden of obtaining prior authorization for psychotropic medications on psychiatric prescribers further stretches an already scarce resource. 1. 75% of NC counties have LESS THAN HALF the number of prescribers they need to meet county needs. 2. NC is short nearly 1,000 prescribers to fill this gap 3. Because of this shortage, psychiatric prescribing is frequently performed by primary care physicians. A prior-authorization requirement adds to the burden of taking care of this vulnerable population and will likely reduce the likelihood that primary care physicians will be willing to fill this prescriber gap, further worsening access to psychotropic medication management for this population.
3. NC has other tools to effectively manage psychotropic medications in the Medicaid population. 1. A+KIDS and ASAP are programs which require registration/monitoring for patients on antipsychotics medications and provides ample data to assist in identifying physicians with prescribing practices which may not be cost effective. 2. MCOs and CCNC can retrospectively analyze the prescribing patterns of psychiatric prescribers and primary care prescribers respectively. MCOs can work with prescribers to reward cost saving prescribing patterns and can require plans of correction for those whose prescribing practices fall outside of the standard of care. CCNC can identify prescribers who need targeted education around drug selection. Patients were stratified according to their pre-initiation visits to community mental health centers (CMHCs) that target those with the most serious mental illness: CMHC-attenders (at least 2 visits) and non-attenders (fewer than 2 visits). Changes in rates of medication discontinuation, outpatient, emergency room and hospital visits before and after drug initiation were estimated.
Methods

Results
CMHC-attenders had substantially higher rates of comorbidity and use of medications and health services than non-attenders. The policy was associated with increased medication discontinuation in both groups; reductions in psychiatric visits after discontinuing medication among CMHC-attenders (−64/100 patients/month; p<.05); and increases in emergency room visits after discontinuing medication among non-attenders (16/100 patients/month; p<.05). During the 8-month follow-up, the policy had no detectable impact on risk of hospitalization.
Conclusion
The Maine prior-authorization policy was associated with increased medication discontinuation and subsequent changes in use of health services. Though small, these unintended policy effects raise quality of care concerns for a group of very vulnerable patients. Long-term consequences of prior-authorization policies on patient outcomes warrant further investigation.
Background Executive Summary
The Ohio Department of Jobs and Family Services (ODJFS) has under consideration a requirement for prior authorization for the prescription of certain psychotropic drugs for patients with schizophrenia, bipolar disorder, and other serious forms of mental illness. This report is an update of a previously released report assessing the likely impact of such a policy. This revised report reflects modifications to the prior authorization policy currently under consideration by ODJFS, data on the number of severely mentally ill patients in Ohio provided to the researchers by ODJFS, and clarification of Maine's prior authorization policy which acts as a benchmark for the analysis reported here.
Alleged Savings
Originally, ODJFS claimed that a prior authorization policy applicable to Medicaid Managed Care patients considered for inclusion in the FY08-09 biennial budget would save $47 million in Medicaid costs. After two revisions, ODJFS now claims that a prior authorization policy applicable to Medicaid fee-for-service patients will save $6 million. This figure, which has not been documented in any way by ODJFS, includes savings from 8 atypical antipsychotic medications and 44 other medications. Therefore, the savings from prior authorization of the psychotropic drugs will be less than $6 million.
Documented Costs
Much research has focused on the costs caused by the implementation of prior authorization requirements for drugs prescribed for the mentally ill in other states. Application of this research to Ohio enables the quantification of millions of dollars of additional costs as an unintended outcome of a prior authorization program for psychotropic drugs.
Maine's experience with prior authorization provides an important benchmark for assessing the likely impact of such a policy in Ohio. As ODJFS is currently proposing in Ohio, Maine's prior authorization initiative allowed established users of single therapy atypical antipsychotics to be grandfathered, and identified some atypicals as preferred drugs. One difference is that Maine did not provide an exemption for prescriptions written by psychiatrists. This difference is accounted for in the estimates detailed below.
Estimates of the number of persons with schizophrenia and bipolar disorder in the Ohio Medicaid program suggest that approximately 36,000 persons with such diagnoses would be affected by prior authorization requirements. 2) Research by the Harvard Medical School supports an estimate that prior authorization will increase the number of lapses in care for this population by 6%. 3) Other research shows that 80% of persons whose care lapses suffer expensive adverse consequences. 4) These adverse consequences include higher medical costs, hospitalization, lost wages, homelessness, and incarceration. 
Background
Recent data show a maldistribution of psychiatrists in North Carolina and critical shortages in some areas. However, only 11 entire counties have official mental health professional shortage designation.
Methods
This paper presents estimates of the adequacy of the county-level mental health professional workforce. These estimates build on previous work in 4 ways: They account for mental health need as well as provider supply, capture adequacy of the prescriber and nonprescriber workforce, consider mental health services provided by primary care providers, and account for travel across county lines by providers and consumers. Workforce adequacy is measured at the county level by the percentage of need for mental health visits that is met by the current supply of prescribers and nonprescribers.
Results
Ninety-five of North Carolina's 100 counties have unmet need for prescribers. In contrast, only 7 have unmet need for nonprescribers, and these counties have inadequate numbers of prescribers as well. To eliminate the deficit under current national patterns of care, the state would need about 980 more prescribers.
Limitations
Data limitations constrain findings to focus on percentage of met need rather than supplying exact counts of additional professionals needed. Estimates do not distinguish between public and private sectors of care, nor do they embody a standard of care.
Conclusions
North Carolina is working to develop its mental health prescriber workforce. The Affordable Care Act provides new opportunities to develop the mental health workforce, innovative practices involving an efficient mix of professionals, and financing mechanisms to support them.
